EUVIMEDEUVIMED entdecken
Crossref

Patients' and rheumatologists' perceptions on dose reduction of rituximab in rheumatoid arthritis

Delphine Bertrand iD, Anke Deprez, Michaël Doumen, Diederik De Cock, Sofia Pazmino, Anja Marchal, Marc Thelissen, Johan Joly, Elias De Meyst, Barbara Neerinckx, René Westhovens, Patrick Verschueren

Musculoskeletal Care · 2024

DOI: 10.1002/msc.1893 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Musculoskeletal Care, 2024. Verfasst von Delphine Bertrand und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Rituximab, Arthritis, Rheumatoid, Antirheumatic Agents, Rheumatologists. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Fonds Voor Wetenschappelijk Reumaonderzoek/Fonds Pour La Recherche Scientifique En Rhumatologie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The recommended dose of a rituximab course for the treatment of Rheumatoid Arthritis (RA) consists of two infusions of 1000 mg with a 2‐week interval. Evidence is growing that a lower dose could be as effective. We aimed to investigate patients' and rheumatologists' perceptions on dose reduction of rituximab.

Methods

Patients with RA treated with rituximab, and rheumatologists were invited for a qualitative study via individual semi‐structured interviews. Participants were recruited based on purposive sampling to ensure diversity. Interviews were analysed according to the principles of grounded theory and the constant comparative method.

Results

Sixteen patients and 13 rheumatologists were interviewed. Patients and rheumatologists perceived the benefits of rituximab dose reduction for reasons of safety and societal costs. Furthermore, available evidence for the effectiveness of lower doses was mentioned as an argument in favour, in addition to the possibility to tailor the dose based on the patients' clinical manifestations. However, patients and rheumatologists had concerns about the potential loss of effectiveness and quality of life. Moreover, some rheumatologists felt uncomfortable with dose reduction due to insufficient experience with rituximab in general. Patients and rheumatologists emphasised the importance of shared decision‐making, underscoring the pivotal role of physicians in this process by explaining the reasoning behind dose reduction.

Conclusion

Although some concerns on effectiveness were perceived, both patients and rheumatologists saw potential benefits of dose reduction in terms of safety, societal costs, and application of a personalised approach. As a result, most rheumatologists and patients showed a willingness to consider dose reduction strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabArthritis, RheumatoidAntirheumatic AgentsRheumatologistsHumansMaleMiddle AgedFemaleAgedAdultAttitude of Health Personnel

Stichwörter der Autor:innen

dose reductionperceptionqualitative researchrheumatoid arthritisrituximab

Substanzen

RituximabAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium.
  • Department of Public Health and Primary Care, Environment and Health, KU Leuven, Leuven, Belgium.
  • Rheumatology, UZ Leuven, Leuven, Belgium.
  • Biostatistics and Medical Informatics Research Group, Department of Public Health, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussel, Belgium.
  • Department of Chronic Diseases and Metabolism, Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.
  • ReumaNet vzw, Zaventem, Belgium.

ORCID-Profile: Delphine Bertrand

Förderung

  • Fonds Voor Wetenschappelijk Reumaonderzoek/Fonds Pour La Recherche Scientifique En Rhumatologie

Zitieren

APA

Bertrand, D., Deprez, A., Doumen, M., De Cock, D., Pazmino, S., Marchal, A., Thelissen, M., Joly, J., De Meyst, E., Neerinckx, B., Westhovens, R., & Verschueren, P. (2024). Patients' and rheumatologists' perceptions on dose reduction of rituximab in rheumatoid arthritis. Musculoskeletal Care. https://doi.org/10.1002/msc.1893

Vancouver

Bertrand D, Deprez A, Doumen M, De Cock D, Pazmino S, Marchal A, et al. Patients' and rheumatologists' perceptions on dose reduction of rituximab in rheumatoid arthritis. Musculoskeletal Care. 2024. doi:10.1002/msc.1893

BibTeX
@article{Bertrand2024,
  author = {Bertrand, Delphine and Deprez, Anke and Doumen, Michaël and De Cock, Diederik and Pazmino, Sofia and Marchal, Anja and Thelissen, Marc and Joly, Johan and De Meyst, Elias and Neerinckx, Barbara and Westhovens, René and Verschueren, Patrick},
  title = {Patients' and rheumatologists' perceptions on dose reduction of rituximab in rheumatoid arthritis},
  journal = {Musculoskeletal Care},
  year = {2024},
  doi = {10.1002/msc.1893}
}
Kostenlos starten →